Stichting Treant Ziekenhuiszorg

At Stichting Treant Ziekenhuiszorg in Emmen, the Cardiology program focuses strongly on cardiovascular diseases, especially atherosclerotic cardiovascular disease, acute coronary syndrome, and atrial fibrillation. The trials here are largely aimed at improving prevention of major heart and vascular events and at finding safer, more effective ways to manage high-risk patients.

• Studies testing new treatments to lower the risk of heart attack, stroke, and cardiovascular death in people with established atherosclerotic disease.
• Research in acute coronary syndrome and coronary heart disease that examines whether treatment strategies can reduce bleeding while preserving protection from ischemic events.
• Trials in atrial fibrillation looking at stroke prevention and balancing benefit against bleeding risk in patients needing long-term cardiovascular care.

Overall, the site contributes to practical research on better prevention and treatment of serious heart conditions, with a clear emphasis on patient safety and clinical effectiveness.

This research setting also includes studies in heart failure, particularly HFmrEF and HFpEF, where investigators are exploring new ways to reduce cardiovascular complications in people with systemic inflammation. Alongside this, the site is involved in broader efforts to improve outcomes in patients at elevated vascular risk.

• Trials evaluating therapies intended to reduce heart failure events and cardiovascular death in patients with inflammatory risk profiles.
• Research on lipid-related approaches for people with ASCVD to better control long-term cardiovascular risk.
• Studies focused on preventing recurrent major adverse cardiovascular events after prior cardiac disease.

The work at this site reflects a strong interest in preventing progression of chronic cardiovascular illness and improving outcomes for patients with complex heart disease.

Beyond cardiology, the trial portfolio includes nervous system diseases, with research in multiple sclerosis centered on comparing established immune-targeted treatments for relapsing disease. These studies are designed to help clarify which therapy offers the best balance of effectiveness and safety for patients who need advanced treatment.

• Clinical research in relapsing multiple sclerosis assessing whether one anti-CD20 treatment can perform as well as another.
• Work aimed at supporting treatment decisions for patients starting disease-modifying therapy.
• Comparative studies intended to guide more effective long-term management of neurological disease.

This adds a meaningful neurological dimension to the site’s research activity, extending its impact beyond cardiovascular care.

The site is also involved in research on male urogenital diseases, including low-volume metastatic castration-sensitive prostate cancer. These trials are focused on refining treatment duration and reducing unnecessary exposure to therapy, with the goal of preserving quality of life while maintaining disease control.

• Studies assessing whether treatment can be safely reduced or stopped in selected prostate cancer patients.
• Research aimed at limiting toxicity and treatment burden without compromising effectiveness.
• Trials that may help make long-term cancer care more sustainable for patients and clinicians.

This work highlights a patient-centered approach to oncology research, with attention to both clinical benefit and treatment burden.